Literature DB >> 3266339

The effects of continuous administration of murine interleukin-1 alpha in the rat.

I G Otterness1, P A Seymour, H W Golden, J A Reynolds, G O Daumy.   

Abstract

Recombinant murine IL-1 alpha was administered continuously to rats by means of osmotic pumps implanted intraperitoneally. Continuous infusion of rIL-1 alpha in a range between 0.12 and 12.0 micrograms/day for four days was found to produce concentration-dependent weight loss. Behavioral parameters were continuously monitored and recorded at the 3.0 micrograms/day concentration in electronically-monitored activity cages during Days 2 through 5 of rIL-1 alpha administration. Parameters were separated into those affected during the dark phase (active period) or the light phase (resting period). Eating activity was found to be significantly reduced during each dark period through day 5, when compared with either untreated or PBS vehicle-infused animals. During the fourth and fifth days of infusion, however, eating behavior in animals infused with rIL-1 alpha began to increase toward control level in the latter, but not the earlier, half of the dark period. In contrast, drinking behavior was found to be significantly elevated only during the light periods. Continuous infusion of rIL-1 alpha also produced significant reductions in both horizontal locomotor activity (crossovers) and vertical locomotor activity (rears). However, in contrast to the trend toward a return of normal eating behavior, locomotor activity remained decreased through the fifth day of rIL-1 alpha infusion. These results suggest changes that could be produced by IL-1 in chronic inflammatory disease and infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266339     DOI: 10.1016/0031-9384(88)90379-4

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  9 in total

Review 1.  Fatigue in cholestatic liver disease--a perplexing symptom.

Authors:  D Kumar; R K Tandon
Journal:  Postgrad Med J       Date:  2002-07       Impact factor: 2.401

2.  The psychomodulatory action of subpyrogenic doses of interleukin-1beta in conditions of chronic administration to rats.

Authors:  E S Sokolova; V I Lyudyno; A S Simbirtsev; V M Klimenko
Journal:  Neurosci Behav Physiol       Date:  2007-06

3.  Effects of continuously administered murine interleukin-1 alpha: tolerance development and granuloma formation.

Authors:  I G Otterness; H W Golden; W H Brissette; P A Seymour; G O Daumy
Journal:  Infect Immun       Date:  1989-09       Impact factor: 3.441

4.  Feed intake and rumen motility in dwarf goats. Effects of some alpha 2-adrenergic agonists, prostaglandins and posterior pituitary hormones.

Authors:  A S van Miert; C T van Duin
Journal:  Vet Res Commun       Date:  1991       Impact factor: 2.459

5.  Some factors affecting inhibition and restoration of mobility after induction of an acute arthritis in the hamster.

Authors:  I G Otterness; A J Milici; M L Bliven
Journal:  Agents Actions       Date:  1993-11

6.  Comparison of mobility changes with histological and biochemical changes during lipopolysaccharide-induced arthritis in the hamster.

Authors:  I G Otterness; M L Bliven; A J Milici; A R Poole
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Mast cell-dependent anorexia and hypothermia induced by mucosal activation of Toll-like receptor 7.

Authors:  Tomoko Hayashi; Howard B Cottam; Michael Chan; Guangyi Jin; Rommel I Tawatao; Brian Crain; Lisa Ronacher; Karen Messer; Dennis A Carson; Maripat Corr
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-14       Impact factor: 3.619

8.  Effects of interleukin-1beta and lipopolysaccharide on behavior of mice in the elevated plus-maze and open field tests.

Authors:  Artur H Swiergiel; Adrian J Dunn
Journal:  Pharmacol Biochem Behav       Date:  2007-02-16       Impact factor: 3.533

9.  Changes in Mobility of the Golden Hamster with Induction of an IL-1-Induced Arthritis.

Authors:  I G Otterness; M L Bliven; A J Milici
Journal:  Mediators Inflamm       Date:  1994       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.